Abstract
Drug addiction is a major worldwide medical and social problem that continues to escalate. The addiction syndrome is remarkably similar between different drugs of abuse, and can be characterized as a chronic relapsing brain disorder with neurobiological changes that lead to a compulsion to take a drug with loss of control over drug intake. Presently used medications for the treatment of dependence disorders are based on drugs that are either agonists or antagonists of drugs of abuse, and have yielded only limited success. Immunopharmacotherapy is based on the generation or administration of antibodies that are capable of binding the targeted drug before it can reach the brain, whereas replacement strategies based on agonists or antagonists of these drugs generally cause many undesired side effects. A large amount of data has been gathered in recent years on the effects of active and passive immunization against cocaine, nicotine, PCP and methamphetamine in animal models, suggesting potential efficacy of these treatments in humans; and clinical trials are currently underway for vaccines against cocaine and nicotine.
Keywords: Immunopharmacotherapy, neurobiological, antagonists, methamphetamine
Current Drug Discovery Technologies
Title: Development of Immunopharmacotherapy Against Drugs of Abuse
Volume: 1 Issue: 1
Author(s): Michael M. Meijler, Masayuki Matsushita, Peter Wirsching and Kim D. Janda
Affiliation:
Keywords: Immunopharmacotherapy, neurobiological, antagonists, methamphetamine
Abstract: Drug addiction is a major worldwide medical and social problem that continues to escalate. The addiction syndrome is remarkably similar between different drugs of abuse, and can be characterized as a chronic relapsing brain disorder with neurobiological changes that lead to a compulsion to take a drug with loss of control over drug intake. Presently used medications for the treatment of dependence disorders are based on drugs that are either agonists or antagonists of drugs of abuse, and have yielded only limited success. Immunopharmacotherapy is based on the generation or administration of antibodies that are capable of binding the targeted drug before it can reach the brain, whereas replacement strategies based on agonists or antagonists of these drugs generally cause many undesired side effects. A large amount of data has been gathered in recent years on the effects of active and passive immunization against cocaine, nicotine, PCP and methamphetamine in animal models, suggesting potential efficacy of these treatments in humans; and clinical trials are currently underway for vaccines against cocaine and nicotine.
Export Options
About this article
Cite this article as:
Meijler M. Michael, Matsushita Masayuki, Wirsching Peter and Janda D. Kim, Development of Immunopharmacotherapy Against Drugs of Abuse, Current Drug Discovery Technologies 2004; 1 (1) . https://dx.doi.org/10.2174/1570163043484851
DOI https://dx.doi.org/10.2174/1570163043484851 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Aspects of Statin Safety
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Antioxidants in Peripheral Arterial Disease
Current Drug Targets - Cardiovascular & Hematological Disorders Biomarker Assessment in Nutritional Modulation of Oxidative Stress-Induced Cancer Development by Lipid-Related Bioactive Molecules
Recent Patents on Anti-Cancer Drug Discovery Smoking and Cardiovascular System: Cellular Features of the Damage
Current Pharmaceutical Design Cell Immunity in Coronary Artery Disease (CAD)
Current Immunology Reviews (Discontinued) A Review of IGF1 Signaling and IGF1-related Long Noncoding RNAs in Chemoresistance of Cancer
Current Cancer Drug Targets Understanding Respiratory Syncytial Virus Infection to Improve Treatment and Immunity
Current Molecular Medicine Molecular Mechanisms Involved in the Aging of the T-cell Immune Response
Current Genomics Dexmedetomidine Use in General Anaesthesia
Current Drug Targets Environmental Factors and Hypertension
Current Pharmaceutical Design CD31+ Circulating Angiogenic Cell Number and Subtypes are Reduced in Individuals with Chronic Stroke
Current Neurovascular Research Regulation of Myocardial Extracellular Matrix Dynamic Changes in Myocardial Infarction and Postinfarct Remodeling
Current Cardiology Reviews Pulmonary Rehabilitation as Evaluated by Clinical Trials: An Overview
Reviews on Recent Clinical Trials Essential Hypertension, Cerebral White Matter Pathology and Ischemic Stroke
Current Medicinal Chemistry Anti-inflammatory Treatment of Acute Coronary Syndromes
Current Pharmaceutical Design Synthesis, Characterization and Evaluation of Gemfibrozil-Stilbene Hybrid as Antioxidant Agent
Letters in Drug Design & Discovery Commercially Available, FDA-approved Epigenetic Modifiers As Therapeutic Agents in Bacterial Infection
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) New Approaches for the Treatment of Chagas Disease
Current Drug Targets Prevention of Bacterial Endocarditis
Cardiovascular & Hematological Disorders-Drug Targets Hybrid Docking-QSAR Studies of 1, 4-dihydropyridine-3, 5-Dicarboxamides as Potential Antitubercular Agents
Current Computer-Aided Drug Design